Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$3.69B |
| 2 |
Abbott
ABT
|
+$3.65B |
| 3 |
Qualcomm
QCOM
|
+$3.54B |
| 4 |
Procter & Gamble
PG
|
+$3.42B |
| 5 |
Accenture
ACN
|
+$3.28B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$2.86B |
| 2 |
AbbVie
ABBV
|
+$2.71B |
| 3 |
Valero Energy
VLO
|
+$1.86B |
| 4 |
Lockheed Martin
LMT
|
+$916M |
| 5 |
Halliburton
HAL
|
+$856M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 10.68% |
| 3 | Healthcare | 10.19% |
| 4 | Industrials | 8.63% |
| 5 | Consumer Discretionary | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Vor Biopharma
VOR
$1.04B
| $396K | ﹤0.01% |
+22,216
| New | +$313K |
|
3177
Inhibikase Therapeutics
IKT
$366M
| $395K | ﹤0.01% |
235,414
+83,116
| +55% | +$148K |
|
3178
MainStreet Bancshares
MNSB
$167M
| $395K | ﹤0.01% |
17,801
-2,764
| -13% | -$59.6K |
|
3179
Codexis
CDXS
$135M
| $395K | ﹤0.01% |
242,211
-32,687
| -12% | -$46.6K |
|
3180
FinWise Bancorp
FINW
$189M
| $391K | ﹤0.01% |
24,649
-2,769
| -10% | -$47.2K |
|
3181
Fennec Pharmaceuticals
FENC
$347M
| $391K | ﹤0.01% |
63,537
+6,288
| +11% | +$48.5K |
|
|
UBFO
3182
DELISTED
United Security Bancshares
UBFO
| $388K | ﹤0.01% |
36,885
-3,566
| -9% | -$37.5K |
|
3183
Gencor Industries
GENC
$223M
| $387K | ﹤0.01% |
25,827
-3,199
| -11% | -$46.7K |
|
3184
Acme United Corp
ACU
$206M
| $387K | ﹤0.01% |
8,608
-1,040
| -11% | -$45.3K |
|
3185
CVRx
CVRX
$126M
| $386K | ﹤0.01% |
40,821
-5,120
| -11% | -$37.5K |
|
3186
Inseego
INSG
$108M
| $386K | ﹤0.01% |
34,718
-181
| -0.5% | -$2.04K |
|
3187
BV Financial
BVFL
$177M
| $386K | ﹤0.01% |
20,156
-4,693
| -19% | -$89.1K |
|
3188
Ocugen
OCGN
$410M
| $384K | ﹤0.01% |
212,094
+40,371
| +24% | +$69.8K |
|
3189
Nuvectis Pharma
NVCT
$609M
| $384K | ﹤0.01% |
49,645
+5,623
| +13% | +$48.2K |
|
3190
Alto Neuroscience
ANRO
$1.04B
| $383K | ﹤0.01% |
17,018
-46
| -0.3% | -$853 |
|
|
SNWV
3191
SANUWAVE Health Inc
SNWV
$51M
| $379K | ﹤0.01% |
21,935
-2,463
| -10% | -$60.8K |
|
3192
Eagle Bancorp Montana
EBMT
$186M
| $377K | ﹤0.01% |
18,336
-2,742
| -13% | -$58.5K |
|
3193
LifeMD
LFMD
$179M
| $377K | ﹤0.01% |
104,509
-8,806
| -8% | -$30.5K |
|
3194
CF Bankshares
CFBK
$217M
| $377K | ﹤0.01% |
13,497
-528
| -4% | -$15.4K |
|
3195
Pioneer Bancorp
PBFS
$445M
| $375K | ﹤0.01% |
26,920
-4,350
| -14% | -$60.8K |
|
3196
Medallion Financial
MFIN
$226M
| $371K | ﹤0.01% |
43,313
-4,005
| -8% | -$39.4K |
|
3197
Relmada Therapeutics
RLMD
$544M
| $369K | ﹤0.01% |
53,081
| – | – |
|
3198
EVI Industries
EVI
$180M
| $365K | ﹤0.01% |
17,758
+2,462
| +16% | +$55.1K |
|
3199
Hamilton Beach Brands
HBB
$302M
| $363K | ﹤0.01% |
19,179
-2,525
| -12% | -$46.1K |
|
3200
Finward Bancorp
FNWD
$193M
| $362K | ﹤0.01% |
9,982
-399
| -4% | -$14.6K |
|
Similar funds
Charles Schwab's Q1 2026 Portfolio in Review
As of Q1 2026, Charles Schwab held 3,535 positions worth $654B, up 1.7% from $644B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab deployed $21.4B of net new capital in Q1 2026, opening 79 new positions and adding to 1,903 existing holdings. Its largest new stake was JPMorgan Income ETF: 8,679,689 shares worth $400M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Cisco, an estimated $2.86B trimmed.
- Charles Schwab's largest Q1 2026 buy was JPMorgan Income ETF: 8,679,689 shares worth $400M.
- Charles Schwab added most to UnitedHealth in Q1 2026, an estimated $3.69B increase.
- Charles Schwab's biggest Q1 2026 reduction was Cisco, cutting an estimated $2.86B.
- Charles Schwab fully exited Comerica in Q1 2026, selling an estimated $412M.
- Charles Schwab's ten largest holdings make up 22% of its $654B portfolio in Q1 2026.
- Charles Schwab opened 79 new positions and closed 80 in Q1 2026.
- Charles Schwab's portfolio value rose 1.7% quarter-over-quarter to $654B.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.